99 related articles for article (PubMed ID: 2569924)
1. An immunologic profile of young adults with head and neck cancer.
Schantz SP; Liu FJ
Cancer; 1989 Sep; 64(6):1232-7. PubMed ID: 2569924
[TBL] [Abstract][Full Text] [Related]
2. The relationship of circulating IgA to cellular immunity in head and neck cancer patients.
Schantz SP; Liu FJ; Taylor D; Beddingfield N; Weber RS
Laryngoscope; 1988 Jun; 98(6 Pt 1):671-8. PubMed ID: 3259661
[TBL] [Abstract][Full Text] [Related]
3. Immunologic determinants of head and neck cancer response to induction chemotherapy.
Schantz SP; Savage HE; Racz T; Liu FJ; Brown BW; Rossen RD; Hong WK
J Clin Oncol; 1989 Jul; 7(7):857-64. PubMed ID: 2472470
[TBL] [Abstract][Full Text] [Related]
4. Total lymphocyte and T lymphocyte subpopulation levels in head and neck squamous cell carcinomas.
Soysal V; Yigitbasi OG; Alper M; Patiroglu T; Güney E
J Exp Clin Cancer Res; 1998 Jun; 17(2):207-12. PubMed ID: 9700582
[TBL] [Abstract][Full Text] [Related]
5. Immunologic evaluation and prognosis in patients with head and neck cancer.
Hilal EY; Wanebo HJ; Pinsky CM; Middleman P; Strong EW; Oettgen HF
Am J Surg; 1977 Oct; 134(4):468-73. PubMed ID: 303057
[TBL] [Abstract][Full Text] [Related]
6. Cell surface markers for T and B lymphocytes activation and adhesion as putative prognostic biomarkers for head and neck squamous cell carcinoma.
Andrade MC; Ferreira SB; Gonçalves LC; De-Paula AM; de Faria ES; Teixeira-Carvalho A; Martins-Filho OA
Hum Immunol; 2013 Dec; 74(12):1563-74. PubMed ID: 23994583
[TBL] [Abstract][Full Text] [Related]
7. Characterization of tumor-associated T-lymphocyte subsets and immune checkpoint molecules in head and neck squamous cell carcinoma.
Lechner A; Schlößer H; Rothschild SI; Thelen M; Reuter S; Zentis P; Shimabukuro-Vornhagen A; Theurich S; Wennhold K; Garcia-Marquez M; Tharun L; Quaas A; Schauss A; Isensee J; Hucho T; Huebbers C; von Bergwelt-Baildon M; Beutner D
Oncotarget; 2017 Jul; 8(27):44418-44433. PubMed ID: 28574843
[TBL] [Abstract][Full Text] [Related]
8. Correlation of preoperative immunologic test results with recurrence in patients with head and neck cancer.
Ryan RE; Neel HB; Ritts RE
Otolaryngol Head Neck Surg (1979); 1980; 88(1):58-63. PubMed ID: 6967203
[TBL] [Abstract][Full Text] [Related]
9. Identification of lymphocyte subsets and natural killer cells in head and neck cancers. An immunohistological study using monoclonal antibodies.
Harabuchi Y; Yamanaka N; Kataura A
Arch Otorhinolaryngol; 1985; 242(1):89-97. PubMed ID: 3899069
[TBL] [Abstract][Full Text] [Related]
10. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
11. Major immunoglobulin ratios in carcinoma of the head and neck.
Katz AE; Nysather JO; Harker LA
Ann Otol Rhinol Laryngol; 1978; 87(3 Pt 1):412-5. PubMed ID: 655583
[TBL] [Abstract][Full Text] [Related]
12. T-cell subsets and natural killer cell function with squamous cell carcinoma of the head and neck.
Strome M; Clark JR; Fried MP; Rodliff S; Blazar BA
Arch Otolaryngol Head Neck Surg; 1987 Oct; 113(10):1090-3. PubMed ID: 3497652
[TBL] [Abstract][Full Text] [Related]
13. Identification of subsets of lymphocytes infiltrating head and neck tumor tissue: a preliminary report.
Rabin BS; Johnson J; Claassen D
Laryngoscope; 1984 May; 94(5 Pt 1):688-90. PubMed ID: 6232437
[TBL] [Abstract][Full Text] [Related]
14. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy.
Manyam BV; Gastman B; Zhang AY; Reddy CA; Burkey BB; Scharpf J; Alam DS; Fritz MA; Vidimos AT; Koyfman SA
J Am Acad Dermatol; 2015 Aug; 73(2):221-7. PubMed ID: 26028524
[TBL] [Abstract][Full Text] [Related]
15. Interferon activity and its characterization in the sera of patients with head and neck cancer.
Sato M; Yoshida H; Yanagawa T; Yura Y; Urata M; Atsumi M; Furumoto N; Hayashi Y; Takegawa Y
Cancer; 1984 Oct; 54(7):1239-51. PubMed ID: 6205740
[TBL] [Abstract][Full Text] [Related]
16. Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer.
Schantz SP; Brown BW; Lira E; Taylor DL; Beddingfield N
Cancer Immunol Immunother; 1987; 25(2):141-8. PubMed ID: 3499224
[TBL] [Abstract][Full Text] [Related]
17. Immunobiologic staging of patients with carcinoma of the head and neck.
Katz AE
Laryngoscope; 1983 Apr; 93(4):445-63. PubMed ID: 6339850
[TBL] [Abstract][Full Text] [Related]
18. [Illness stage and IgA-anti-Fab/F(ab')2 autoantibody activity in serum of patients with malignant head-neck tumors].
Lorenz KJ; Süsal C; Opelz G; Maier H
Laryngorhinootologie; 1996 Dec; 75(12):764-8. PubMed ID: 9081283
[TBL] [Abstract][Full Text] [Related]
19. Distribution of immunoglobulins in squamous cell carcinoma of the head and neck.
Neuchrist C; Kornfehl J; Grasl M; Lassmann H; Kraft D; Ehrenberger K; Scheiner O
Int Arch Allergy Immunol; 1994 May; 104(1):97-100. PubMed ID: 7950411
[TBL] [Abstract][Full Text] [Related]
20. Serum immunoglobulin levels in patients with head and neck cancer (IgE, IgA, IgM, IgG).
Vinzenz K; Pavelka R; Schönthal E; Zekert F
Oncology; 1986; 43(5):316-22. PubMed ID: 3763126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
